MCID: MYS003
MIFTS: 65

Myasthenia Gravis malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Myasthenia Gravis

About this section
Sources:
11Disease Ontology, 13DISEASES, 25Genetics Home Reference, 26GTR, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 34LifeMap Discovery®, 37MedlinePlus, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 48NINDS, 49Novoseek, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Myasthenia Gravis:

Name: Myasthenia Gravis 34 11 47 25 48 53 26 49 37 38 13 67
Autoimmune Myasthenia Gravis 53
 
Acquired Myasthenia 53
Mg 25

Characteristics:

Orphanet epidemiological data:

53
myasthenia gravis:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:437
ICD1029 G70.0, G70.00
ICD9CM31 358.0, 358.00
MeSH38 D009157
NCIt44 C60989
Orphanet53 ORPHA589
ICD10 via Orphanet30 G70.0
MESH via Orphanet39 D009157
UMLS via Orphanet68 C0026896

Summaries for Myasthenia Gravis

About this section
MedlinePlus:37 Myasthenia gravis is a disease that causes weakness in your voluntary muscles. these are the muscles that you control. for example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. you can also have weakness in other muscles. this weakness gets worse with activity, and better with rest. myasthenia gravis is an autoimmune disease. your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. this makes your muscles weaker. other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. with treatment, the muscle weakness often gets much better. medicines can help improve nerve-to-muscle messages and make muscles stronger. other drugs keep your body from making so many abnormal antibodies. these medicines can have major side effects, so they should be used carefully. there are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. sometimes, surgery to take out the thymus gland helps. some people with myasthenia gravis go into remission. this means that they do not have symptoms. the remission is usually temporary, but sometimes it can be permanent. nih: national institute of neurological disorders and stroke

MalaCards based summary: Myasthenia Gravis, also known as autoimmune myasthenia gravis, is related to addison's disease and hashimoto thyroiditis, and has symptoms including Array, Array and Array. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways are Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics and Agrin Interactions at Neuromuscular Junction. The drugs pyridostigmine bromide and cyclosporine have been mentioned in the context of this disorder. Affiliated tissues include thymus, eye and testes, and related mouse phenotypes are craniofacial and liver/biliary system.

Genetics Home Reference:25 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.

NINDS:48 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. Symptoms vary in type and intensity.

Wikipedia:70 Myasthenia gravis (MG) is a long term neuromuscular disease that leads to varying degrees of skeletal... more...

Related Diseases for Myasthenia Gravis

About this section

Diseases in the Myasthenia Gravis family:

Myasthenia Gravis Congenital Juvenile Myasthenia Gravis
Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 474)
idRelated DiseaseScoreTop Affiliating Genes
1addison's disease29.9IFNG, IL10, IL2, TNF
2hashimoto thyroiditis29.9CTLA4, IFNG, IL4
3exophthalmos29.6IFNG, IL2, IL4, TNF
4churg-strauss syndrome29.5IFNG, IL10, IL4, TNF
5systemic lupus erythematosus28.7CTLA4, IFNG, IL10, IL2, IL4, TNF
6rheumatoid arthritis28.1CTLA4, IFNG, IL10, IL2, IL4, TNF
7juvenile myasthenia gravis12.3
8transient neonatal myasthenia gravis12.3
9adult-onset myasthenia gravis12.3
10rippling muscle disease with myasthenia gravis12.2
11neonatal myasthenia gravis12.2
12myasthenia gravis with thymus hyperplasia12.2
13myasthenia gravis congenital12.1
14myasthenia gravis, limb-girdle12.0
15thymoma11.6
16congenital myasthenic syndrome11.6
17neuromuscular disease11.6
18rippling muscle disease11.4
19paraneoplastic syndromes11.4
20dysphagia11.4
21escobar syndrome11.1
22thymus cancer11.1
23swallowing disorders11.1
24myasthenic syndrome, congenital, 1011.0
25myasthenic syndrome, congenital, 6, presynaptic11.0
26piepkorn karp hickok syndrome10.7IL10, TNF
27congenital myasthenic syndrome associated with acetylcholine receptor deficiency10.6CHRNA1, CHRNE
28linitis plastica10.5IL2, TNF
29myasthenic syndrome, congenital, 4c, associated with acetylcholine receptor deficiency10.5CHRNE, RAPSN
30primary angle-closure glaucoma10.5CHRNG, MUSK
31epileptic encephalopathy, early infantile, 2510.5CHRNE, RAPSN
32leukemia, chronic lymphocytic 110.5MUSK, RAPSN
33panuveitis10.5CTLA4, IL10, TNF
34idiopathic central precocious puberty10.5CTLA4, IL10, TNF
35mitochondrial complex iii deficiency, nuclear type 210.5CHRNE, MUSK, RAPSN
36panner disease10.4IFNG, TNF
37pasteurellosis10.4IFNG, TNF, TTN
38multiple pterygium syndrome, lethal type10.4CHRNA1, CHRNG, RAPSN
39baetz-greenwalt syndrome10.4IFNG, TNF
40myoclonus epilepsy10.4IFNG, IL4
41hernia of ovary and fallopian tube10.4IFNG, IL10, TNF
42pseudoretinitis pigmentosa10.4IFNG, IL10, TNF
43sensorineural hearing loss10.4IFNG, IL10, TNF
44psychologic dyspareunia10.4IFNG, IL10, TNF
45mastocytosis cutaneous with short stature conductive hearing loss and microtia10.4IFNG, IL10, TNF
46leukostasis10.4IFNG, IL10, TNF
47autoimmune pancreatitis10.4IFNG, TNF
48dementia - subcortical10.4IFNG, IL10, TNF
49gastric dilatation10.4IFNG, IL10, TNF
50bile duct signet ring cell carcinoma10.4IFNG, IL10, TNF

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to myasthenia gravis

Symptoms for Myasthenia Gravis

About this section

Human phenotypes related to Myasthenia Gravis:

 53 (show all 27)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness53 Very frequent (99-80%)
2 ptosis53 Frequent (79-30%)
3 ophthalmoparesis53 Frequent (79-30%)
4 diplopia53 Frequent (79-30%)
5 abnormality of the thymus53 Frequent (79-30%)
6 dysarthria53 Frequent (79-30%)
7 bulbar palsy53 Frequent (79-30%)
8 dysphagia53 Frequent (79-30%)
9 dyspnea53 Frequent (79-30%)
10 single fiber emg abnormality53 Frequent (79-30%)
11 acetylcholine receptor antibody positivity53 Frequent (79-30%)
12 myositis53 Frequent (79-30%)
13 hearing impairment53 Occasional (29-5%)
14 hyperthyroidism53 Occasional (29-5%)
15 hashimoto thyroiditis53 Occasional (29-5%)
16 rheumatoid arthritis53 Occasional (29-5%)
17 systemic lupus erythematosus53 Occasional (29-5%)
18 glycosuria53 Occasional (29-5%)
19 paresthesia53 Occasional (29-5%)
20 primary adrenal insufficiency53 Occasional (29-5%)
21 hyperacusis53 Occasional (29-5%)
22 psychosis53 Very rare (<4-1%)
23 acrocyanosis53 Very rare (<4-1%)
24 seizures53 Very rare (<4-1%)
25 hemolytic anemia53 Very rare (<4-1%)
26 hepatitis53 Very rare (<4-1%)
27 pure red cell aplasia53 Very rare (<4-1%)

UMLS symptoms related to Myasthenia Gravis:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, muscle weakness, facial paresis, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Myasthenia Gravis

About this section

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 81)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AzathioprineapprovedPhase 4, Phase 3165446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
2
Prednisoneapproved, vet_approvedPhase 4, Phase 3135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
3glucocorticoidsPhase 4, Phase 34920
4Hormone AntagonistsPhase 4, Phase 312778
5Immunosuppressive AgentsPhase 4, Phase 3, Phase 212770
6AntibodiesPhase 4, Phase 3, Phase 26045
7Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110627
8Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 312767
9HormonesPhase 4, Phase 313979
10ImmunoglobulinsPhase 4, Phase 3, Phase 26045
11AntimetabolitesPhase 4, Phase 3, Phase 211774
12Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 27171
13Antineoplastic Agents, HormonalPhase 4, Phase 35407
14Immunoglobulins, IntravenousPhase 4, Phase 3, Phase 2324
15gamma-GlobulinsPhase 4, Phase 3, Phase 2317
16Rho(D) Immune GlobulinPhase 4, Phase 3, Phase 2317
17Anti-Inflammatory AgentsPhase 4, Phase 310355
18
Mycophenolic acidapprovedPhase 393924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
19
Leflunomideapproved, investigationalPhase 36775706-12-63899
Synonyms:
210165-51-8
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl
4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl)
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
75706-12-6
A77 1486
AB00052389
AC-6796
AC1L1GYK
AC1Q2EVA
AKOS000265193
AP-501/42475599
Arava
Arava (TN)
Arava, Leflunomide
Aventis Behring Brand of Leflunomide
Aventis Brand of Leflunomide
Aventis Pharma Brand of Leflunomide
BIDD:PXR0189
BPBio1_000930
BRD-K78692225-001-03-9
BSPBio_000844
C045463
C07905
CAS-75706-12-6
CHEBI:6402
CHEMBL960
CID3899
D00749
DB01097
DivK1c_000916
EU-0100649
HMS1570K06
HMS1922M06
HMS2090O12
HMS502N18
HSDB 7289
HWA 486
HWA-486
Hoechst Brand of Leflunomide
I06-2131
IDI1_000916
KBio1_000916
KBio2_000802
KBio2_003370
KBio2_005938
KBioSS_000802
L 5025
L5025_SIGMA
 
LS-86580
Leflunomid
Leflunomida
Leflunomida [INN-Spanish]
Leflunomide
Leflunomide (JAN/USAN/INN)
Leflunomide [USAN:INN]
Leflunomidum
Leflunomidum [INN-Latin]
Lefunomide
Lefunomide [INN-Spanish]
Lefunomide [Inn-Spanish]
Lopac-L-5025
Lopac0_000649
MLS-0003109.0001
MLS000069648
MLS001076267
MolPort-002-345-613
N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
NCGC00015610-01
NCGC00015610-02
NCGC00015610-03
NCGC00015610-07
NCGC00015610-12
NCGC00022625-03
NCGC00022625-04
NCGC00022625-05
NCGC00022625-06
NCGC00022625-07
NCGC00022625-08
NINDS_000916
NSC677411
Prestwick0_000772
Prestwick1_000772
Prestwick2_000772
Prestwick3_000772
Prestwick_87
RS-34821
S1247_Selleck
SMR000058209
SPBio_002783
SPECTRUM1503927
SU 101
SU 101 (pharmaceutical)
SU-101
SU101
Spectrum5_000850
Spectrum_000322
TL8005179
UNII-G162GK9U4W
ZINC00004840
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
leflunomide
lefunamide
20
Mycophenolate mofetilapproved, investigationalPhase 3939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
21
BenzocaineapprovedPhase 318921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
22
rituximabapprovedPhase 3, Phase 1, Phase 21654174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
23
RocuroniumapprovedPhase 3261119302-91-9, 143558-00-3441290
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
 
DB00728
Esmeron
HMS2090E03
NCGC00167433-01
Rocuronium
Rocuronium bromide
Zemuron
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
24
Tacrolimusapproved, investigationalPhase 31074104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
25
Methylprednisoloneapproved, vet_approvedPhase 3115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
26
Guaifenesinapproved, vet_approvedPhase 361693-14-13516
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
Amonidren
Amonidrin
Aresol
Benylin-E
Bronchol
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
 
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphesin
Hustosil
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
Pneumomist
Propanosedyl
Reduton
Robitussin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
guaiphenesin
p-Cresyl acetate
27
Prednisoloneapproved, vet_approvedPhase 3115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
28tannic acidapproved, NutraceuticalPhase 31892
29Cholinesterase InhibitorsPhase 3570
30Antibiotics, AntitubercularPhase 36972
31Cholinergic AgentsPhase 3, Phase 1, Phase 23846
32Pyridostigmine BromidePhase 325101-26-8
33Neurotransmitter AgentsPhase 3, Phase 1, Phase 217734
34Anti-Bacterial AgentsPhase 310884
35Potassium Channel BlockersPhase 3176
36Neuromuscular Nondepolarizing AgentsPhase 3248
37Peripheral Nervous System AgentsPhase 322776
38Neuromuscular Blocking AgentsPhase 3414
39Neuromuscular AgentsPhase 31129
403,4-diaminopyridinePhase 319
41Prednisolone acetatePhase 31153
42Methylprednisolone HemisuccinatePhase 31153
43Methylprednisolone acetatePhase 31153
44Chlorpheniramine, phenylpropanolamine drug combinationPhase 3616
45Prednisolone hemisuccinatePhase 31153
46VaccinesPhase 3, Phase 1, Phase 26428
47Calcineurin InhibitorsPhase 31597
48Prednisolone phosphatePhase 31153
49BromidesPhase 3606
50Immunoglobulin GPhase 3265

Interventional clinical trials:

(show top 50)    (show all 64)
idNameStatusNCT IDPhase
1Intravenous Immunoglobulin and Plasma Exchange in Myasthenia GravisCompletedNCT01179893Phase 4
2Study Comparing Two Tapering Strategies of Prednisone in Myasthenia GravisActive, not recruitingNCT00987116Phase 4
3The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand ThymectomyUnknown statusNCT01727193Phase 3
4Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia GravisCompletedNCT00306033Phase 3
5Mycophenolate Mofetil in Myasthenia GravisCompletedNCT00285350Phase 3
6Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone TherapyCompletedNCT00294658Phase 3
7Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia GravisCompletedNCT00515450Phase 3
8A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia GravisCompletedNCT01325571Phase 3
9Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)CompletedNCT01997229Phase 3
10FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) PatientsCompletedNCT00309088Phase 3
11A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.CompletedNCT00408213Phase 3
12A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia GravisCompletedNCT00683969Phase 3
13An Open Study for Steroid Resistant, Non-Thymectomized MG PatientsCompletedNCT00309101Phase 3
14A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)CompletedNCT01377922Phase 3
15Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac ArrestCompletedNCT01719770Phase 3
16A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia GravisRecruitingNCT02950155Phase 3
17A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsRecruitingNCT02413580Phase 3
18A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)RecruitingNCT02774239Phase 3
19Electromyography in Patients on Chronic Pyridostigmine TherapyRecruitingNCT02364180Phase 3
20Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)RecruitingNCT02970162Phase 3
21ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia GravisActive, not recruitingNCT02301624Phase 3
22Efficacy of Prednisone In the Treatment of Ocular MyastheniaTerminatedNCT00995722Phase 3
23Efficacy of Methotrexate in Myasthenia GravisCompletedNCT00814138Phase 2
24A Pilot Trial of Rituxan in Refractory Myasthenia GravisCompletedNCT00619671Phase 1, Phase 2
25Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisCompletedNCT00774462Phase 2
26The Evaluation of Belimumab in Myasthenia Gravis (MG)CompletedNCT01480596Phase 2
27Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia GravisRecruitingNCT02609022Phase 1, Phase 2
28Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia GravisRecruitingNCT02565576Phase 2
29Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia GravisRecruitingNCT02100969Phase 2
30A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessRecruitingNCT02965573Phase 2
31Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisRecruitingNCT02473965Phase 2
32A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia GravisRecruitingNCT02473952Phase 2
33The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal TumorRecruitingNCT02317224Phase 2
34Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)RecruitingNCT02102594Phase 2
35Phase II Trial of Rituximab In Myasthenia GravisActive, not recruitingNCT02110706Phase 2
36Sulfamethoxazole for the Treatment of Primary PREPL DeficiencyEnrolling by invitationNCT02640443Phase 2
37Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia GravisTerminatedNCT00727194Phase 2
38Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia GravisTerminatedNCT01268280Phase 2
39Exercise for Stable Myasthenia GravisRecruitingNCT01047761Phase 1
40Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia GravisTerminatedNCT00424489Phase 1
41A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia GravisUnknown statusNCT01555580Early Phase 1
42Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia GravisUnknown statusNCT00997412
43Serum Auto-AntibodiesUnknown statusNCT00704626
44The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal EsophagectomyUnknown statusNCT00373919
45Inherited Myokymia: A Clinical and Genetic Study of a FamilyUnknown statusNCT01250704
46Perception and Multisensory Integration in Neurological Patients Using fMRIUnknown statusNCT01469858
47Therapeutic Plasma Exchange in MGCompletedNCT01927692
48Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-FCompletedNCT02470364
49Tissue Repository for Studies of Myasthenia GravisRecruitingNCT02902536
50Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia GravisRecruitingNCT02066519

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS67/NDF-RT45:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells


Cochrane evidence based reviews: myasthenia gravis

Genetic Tests for Myasthenia Gravis

About this section

Genetic tests related to Myasthenia Gravis:

id Genetic test Affiliating Genes
1 Myasthenia Gravis26

Anatomical Context for Myasthenia Gravis

About this section

MalaCards organs/tissues related to Myasthenia Gravis:

35
Thymus, Eye, Testes, Skeletal muscle, T cells, B cells, Thyroid

Animal Models for Myasthenia Gravis or affiliated genes

About this section

MGI Mouse Phenotypes related to Myasthenia Gravis:

40 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.4ACHE, IFNG, IL10, IL4, RYR1, TNF
2MP:00053708.3AKAP12, CTLA4, IFNG, IL10, IL2, IL4
3MP:00030128.3ACHE, CHRNE, IFNG, IL10, IL2, IL4
4MP:00053908.0CHRNA1, CTLA4, IFNG, IL10, IL4, MUSK
5MP:00028737.6AGRN, AKAP12, CTLA4, IFNG, IL10, IL4
6MP:00053857.6AGRN, AKAP12, CTLA4, IFNG, IL10, IL2
7MP:00053697.5ACHE, AGRN, AKAP12, CHRNE, CHRNG, IFNG
8MP:00107717.5CHRNG, CTLA4, IFNG, IL10, IL4, MUSK
9MP:00053817.1CTLA4, IFNG, IL10, IL2, IL4, RYR1
10MP:00053786.7ACHE, AGRN, CHRNE, CHRNG, IFNG, IL10
11MP:00053876.6AKAP12, CTLA4, IFNG, IL10, IL2, IL4
12MP:00053886.5ACHE, AGRN, AKAP12, CHRNE, CHRNG, CTLA4
13MP:00036316.3ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG
14MP:00053866.1ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG
15MP:00053976.0ACHE, AKAP12, CTLA4, IFNG, IL10, IL2
16MP:00053765.5ACHE, AGRN, CHRNG, CTLA4, IFNG, IL10
17MP:00107685.0ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG

Publications for Myasthenia Gravis

About this section

Articles related to Myasthenia Gravis:

(show top 50)    (show all 1409)
idTitleAuthorsYear
1
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. (28075449)
2017
2
Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma. (27076925)
2016
3
Prevalence and clinical aspects of immigrants with Myasthenia Gravis in northern Europe. (27641227)
2016
4
Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations. (26562150)
2015
5
Myasthenia gravis is a rare but treatable disease. (26543935)
2015
6
Impaired post-tetanic potentiation of muscle twitch in myasthenia gravis. (26547355)
2015
7
Molecular docking cannot accurately predict drug off-target effects: Implications for the role of voriconazole in the exacerbation of myasthenia gravis. (24127354)
2014
8
Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis. (24399309)
2014
9
Thymic tumours associated with Myasthenia gravis: a long term observation study of operated patients. (23944622)
2013
10
Leg pain in a patient with myasthenia gravis. (23613264)
2013
11
Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis. (23184497)
2013
12
Tuberculosis in myasthenia gravis. (23232007)
2013
13
Myasthenia gravis developing in an HIV-negative patient with Kaposi's sarcoma. (23010878)
2013
14
Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. (23535158)
2013
15
Chronic urticaria in myasthenia gravis patients - More than occasional coexistence? (23972403)
2013
16
Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis. (23312969)
2013
17
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. (24296278)
2013
18
Fracture rate in patients with myasthenia gravis: the general practice research database. (22531999)
2013
19
Unilateral extended thoracoscopic thymectomy for nontumoral myasthenia gravis--a new standard. (22920527)
2012
20
Low-dose glucocorticoid therapy complements the pituitary-adrenocortical system and reduces anxiety and insomnia in myasthenia gravis patients. (22240858)
2012
21
Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. (22883288)
2012
22
Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). (22875151)
2012
23
Investigation for RAPSN and DOK-7 mutations in a cohort of seronegative myasthenia gravis patients. (21305573)
2011
24
Cholinergic crisis after neostigmine administration in a dog with acquired focal myasthenia gravis. (22316202)
2011
25
Thymoma: inter-relationships among World Health Organization histology, Masaoka staging and myasthenia gravis and their independent prognostic significance: a single-centre experience. (21093283)
2011
26
Coexistence of primary sclerosing cholangitis in a patient with myasthenia gravis. (22346028)
2011
27
Juvenile myasthenia gravis. (19229875)
2009
28
Widely varying TNF-alpha levels in patients with myasthenia gravis. (19214380)
2009
29
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. (19693092)
2009
30
Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation. (18684515)
2008
31
Myasthenia gravis seronegative for acetylcholine receptor antibodies. (18567857)
2008
32
Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. (17255332)
2007
33
Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. (17335909)
2007
34
Myasthenia gravis masquerading as post-poliomyelitis syndrome. (16546772)
2006
35
HLA-DQB1 allele polymorphism and clinical characteristics of 15 familial myasthenia gravis cases in north China]. (16883535)
2006
36
A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. (16178018)
2005
37
Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. (15168159)
2004
38
Myasthenia gravis in individuals over 40. (14592910)
2003
39
Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis. (12707978)
2003
40
Stiff person syndrome and myasthenia gravis. (11960163)
2002
41
Decreased mRNA expression of TNF-alpha and IL-10 in non-stimulated peripheral blood mononuclear cells in myasthenia gravis. (10809941)
2000
42
Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells. (9467662)
1998
43
A patient with a relapse of myasthenia gravis after a 13-year remission following successful treatment by mediastinal irradiation and corticosteroid therapy]. (7605688)
1995
44
Transient neonatal myasthenia gravis and pyloric stenosis. (8534471)
1995
45
Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. (7578874)
1995
46
Mivacurium chloride and myasthenia gravis. (8155454)
1994
47
Optic neuritis, transverse myelitis, and anti-DNA antibodies nine years after thymectomy for myasthenia gravis. (6610427)
1984
48
Respiratory studies in an infant with neonatal myasthenia gravis. (464928)
1979
49
Neonatal myasthenia gravis: report of two cases and review of the literature. (5309787)
1970
50
The histographic analysis of human muscle biopsies with regard to fiber types. 3. Myotonias, myasthenia gravis, and hypokalemic periodic paralysis. (5815221)
1969

Variations for Myasthenia Gravis

About this section

Expression for genes affiliated with Myasthenia Gravis

About this section
Search GEO for disease gene expression data for Myasthenia Gravis.

Pathways for genes affiliated with Myasthenia Gravis

About this section

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 31)
idSuper pathwaysScoreTop Affiliating Genes
19.7CHRNA1, CHRNE, RYR1
29.5AGRN, CHRNA1, MUSK, RAPSN
39.4IFNG, IL10, TNF
49.4IFNG, IL10, TNF
59.4IFNG, IL10, TNF
6
Show member pathways
9.3IFNG, IL2, TNF
79.3IFNG, IL2, TNF
89.2IFNG, IL10, IL2
99.1IFNG, IL2, IL4
109.1IFNG, IL2, IL4
119.0CTLA4, IFNG, TNF, TNFSF13B
129.0IFNG, IL10, IL2, TNF
13
Show member pathways
9.0IFNG, IL10, IL2, TNF
14
Show member pathways
9.0IFNG, IL10, IL2, TNF
15
Show member pathways
9.0IFNG, IL10, IL2, TNF
16
Show member pathways
8.9IFNG, IL10, IL4, TNF
178.7IFNG, IL10, IL2, IL4
188.7IFNG, IL10, IL2, IL4
19
Show member pathways
8.5CTLA4, IFNG, IL2, IL4, TNF
208.5CTLA4, IL10, IL4, TNF, TNFSF13B
21
Show member pathways
8.4IFNG, IL10, IL2, IL4, TNF
228.4IFNG, IL10, IL2, IL4, TNF
23
Show member pathways
8.4IFNG, IL10, IL2, IL4, TNF
248.4IFNG, IL10, IL2, IL4, TNF
258.4IFNG, IL10, IL2, IL4, TNF
268.3IL10, IL2, IL4, TNF, TNFSF13B
27
Show member pathways
8.2IFNG, IL10, IL2, IL4, TNFSF13B
28
Show member pathways
8.1CTLA4, IFNG, IL10, IL2, IL4, TNF
297.6CTLA4, IFNG, IL10, IL2, IL4, TNF
30
Show member pathways
7.6CTLA4, IFNG, IL10, IL2, IL4, TNF
317.5IFNG, IL2, IL4, MBP, TNF, TNFSF13B

GO Terms for genes affiliated with Myasthenia Gravis

About this section

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1acetylcholine-gated channel complexGO:000589210.5CHRNA1, CHRNE, CHRNG
2neuromuscular junctionGO:003159410.1ACHE, CHRNA1, MUSK, RAPSN
3postsynaptic membraneGO:00452119.5CHRNA1, CHRNE, CHRNG, MUSK, RAPSN
4external side of plasma membraneGO:00098979.4CTLA4, IFNG, IL4, TNF
5cell junctionGO:00300548.7ACHE, AGRN, CHRNA1, CHRNE, CHRNG, MUSK
6extracellular spaceGO:00056157.8ACHE, IFNG, IL10, IL2, IL4, TNF
7plasma membraneGO:00058866.5ACHE, AGRN, AKAP12, CHRNA1, CHRNE, CHRNG

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1receptor biosynthetic processGO:003280010.4IL10, TNF
2negative regulation of cytokine secretion involved in immune responseGO:000274010.4IL10, TNF
3positive regulation of vitamin D biosynthetic processGO:006055710.4IFNG, TNF
4positive regulation of calcidiol 1-monooxygenase activityGO:006055910.4IFNG, TNF
5positive regulation of mononuclear cell migrationGO:007167710.3IL4, TNF
6neuromuscular synaptic transmissionGO:000727410.3CHRNA1, CHRNE, CHRNG
7cation transmembrane transportGO:009865510.3CHRNA1, CHRNE, CHRNG
8regulation of isotype switchingGO:004519110.2IL10, IL4
9negative regulation of B cell proliferationGO:003088910.2CTLA4, IL10
10type 2 immune responseGO:004209210.2IL10, IL4
11negative regulation of nitric oxide biosynthetic processGO:004501910.2IL10, IL4
12skeletal muscle acetylcholine-gated channel clusteringGO:007134010.1MUSK, RAPSN
13B cell costimulationGO:003129610.1IL4, TNFSF13B
14synaptic transmission, cholinergicGO:000727110.1CHRNA1, CHRNE, CHRNG, RAPSN
15positive regulation of chemokine biosynthetic processGO:00450809.9IFNG, IL4, TNF
16chemical synaptic transmission, postsynapticGO:00995659.8CHRNA1, CHRNE, CHRNG
17negative regulation of growth of symbiont in hostGO:00441309.7IFNG, IL10, TNF
18positive regulation of MHC class II biosynthetic processGO:00453489.7IFNG, IL10, IL4
19positive regulation of isotype switching to IgG isotypesGO:00483049.7IFNG, IL2, IL4
20defense response to protozoanGO:00428329.6IFNG, IL10, IL4
21response to nicotineGO:00350949.5CHRNA1, CHRNE, CHRNG
22positive regulation of B cell proliferationGO:00308909.5IL2, IL4, TNFSF13B
23muscle contractionGO:00069369.3CHRNE, CHRNG, RYR1, TTN
24positive regulation of protein phosphorylationGO:00019349.3IL2, IL4, MUSK, TNF
25positive regulation of T cell proliferationGO:00421028.7IFNG, IL2, IL4, TNFSF13B
26immune responseGO:00069557.5CTLA4, IL10, IL2, IL4, MBP, TNFSF13B

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1acetylcholine-activated cation-selective channel activityGO:000488910.3CHRNA1, CHRNE, CHRNG
2acetylcholine receptor activityGO:001546410.3CHRNA1, CHRNE, CHRNG
3acetylcholine bindingGO:004216610.0ACHE, CHRNA1, CHRNE, CHRNG
4ligand-gated ion channel activityGO:00152769.5CHRNA1, CHRNE, CHRNG
5protease bindingGO:00020208.8MBP, RYR1, TNF, TTN
6cytokine activityGO:00051258.0IFNG, IL10, IL2, IL4, TNF, TNFSF13B

Sources for Myasthenia Gravis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet